Exploring the immunomodulatory mechanisms of Shiyiwei Shenqi tablets in NSCLC: N-acetylaspartate as a biomarker for modulating M1/M2 macrophage balance.

IF 8.3 1区 医学 Q1 CHEMISTRY, MEDICINAL
Mingming Wang, Xuewen Yang, Qian Zhang, Yue Qiu, Jiameng Qu, Huarong Xu, Qing Li
{"title":"Exploring the immunomodulatory mechanisms of Shiyiwei Shenqi tablets in NSCLC: N-acetylaspartate as a biomarker for modulating M1/M2 macrophage balance.","authors":"Mingming Wang, Xuewen Yang, Qian Zhang, Yue Qiu, Jiameng Qu, Huarong Xu, Qing Li","doi":"10.1016/j.phymed.2025.157325","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Macrophages, with their dual role in immune regulation and metabolic characteristics, are emerging as the pivotal target in tumor treatments. Shiyiwei Shenqi tablets (SST) is widely used for its immunomodulatory effects in non-small cell lung cancer (NSCLC). However, its mechanism remains unclear.</p><p><strong>Purpose: </strong>This study sought to investigate whether SST regulates immunity in NSCLC through macrophages and to elucidate its underlying mechanisms.</p><p><strong>Methods: </strong>The immunomodulatory mechanisms were initially predicted using the random walk with restart (RWR) algorithm and subsequently verified using the Lewis lung carcinoma model and macrophage cell depletion experiment. The regulatory effects of SST on macrophage phenotype and function were testified through flow cytometry, Western blot, qRT-PCR, ELISA, wound healing, migration, and tube formation assays. Furthermore, non-targeted and targeted metabolomics, combined with molecular studies, were employed to investigate the immunometabolic mechanisms in macrophages.</p><p><strong>Results: </strong>SST treatment markedly impeded tumor progression and identified macrophages as the target cells for enhancing CD8<sup>+</sup> T cell immunity against tumors. Specifically, SST reprogrammed macrophages by polarizing towards an M1-like phenotype while inhibiting the M2-like phenotype, reducing M2-driven angiogenesis and metastasis. Mechanistically, SST inhibited glutamine (Gln) metabolism, with N-acetylaspartate (NAA), a downstream metabolite of Gln, identified as a key regulator across macrophage phenotypes. SST suppressed NAA by downregulating NAT8L and upregulating ASPA, thereby relieving NAA-mediated suppression of NF-κB activation.</p><p><strong>Conclusion: </strong>SST enhanced anti-tumor immunity in NSCLC by promoting M1 macrophages and suppressing M2 macrophages. NAA, a macrophage-derived biomarker, highlighted SST's role in regulating M1/M2 balance.</p>","PeriodicalId":20212,"journal":{"name":"Phytomedicine","volume":"148 ","pages":"157325"},"PeriodicalIF":8.3000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytomedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.phymed.2025.157325","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Macrophages, with their dual role in immune regulation and metabolic characteristics, are emerging as the pivotal target in tumor treatments. Shiyiwei Shenqi tablets (SST) is widely used for its immunomodulatory effects in non-small cell lung cancer (NSCLC). However, its mechanism remains unclear.

Purpose: This study sought to investigate whether SST regulates immunity in NSCLC through macrophages and to elucidate its underlying mechanisms.

Methods: The immunomodulatory mechanisms were initially predicted using the random walk with restart (RWR) algorithm and subsequently verified using the Lewis lung carcinoma model and macrophage cell depletion experiment. The regulatory effects of SST on macrophage phenotype and function were testified through flow cytometry, Western blot, qRT-PCR, ELISA, wound healing, migration, and tube formation assays. Furthermore, non-targeted and targeted metabolomics, combined with molecular studies, were employed to investigate the immunometabolic mechanisms in macrophages.

Results: SST treatment markedly impeded tumor progression and identified macrophages as the target cells for enhancing CD8+ T cell immunity against tumors. Specifically, SST reprogrammed macrophages by polarizing towards an M1-like phenotype while inhibiting the M2-like phenotype, reducing M2-driven angiogenesis and metastasis. Mechanistically, SST inhibited glutamine (Gln) metabolism, with N-acetylaspartate (NAA), a downstream metabolite of Gln, identified as a key regulator across macrophage phenotypes. SST suppressed NAA by downregulating NAT8L and upregulating ASPA, thereby relieving NAA-mediated suppression of NF-κB activation.

Conclusion: SST enhanced anti-tumor immunity in NSCLC by promoting M1 macrophages and suppressing M2 macrophages. NAA, a macrophage-derived biomarker, highlighted SST's role in regulating M1/M2 balance.

探索十益胃参芪片在NSCLC中的免疫调节机制:n -乙酰天冬氨酸作为调节M1/M2巨噬细胞平衡的生物标志物。
背景:巨噬细胞具有免疫调节和代谢特性的双重作用,正在成为肿瘤治疗的关键靶点。十益胃参芪片因其对非小细胞肺癌(NSCLC)的免疫调节作用而被广泛应用。然而,其机制尚不清楚。目的:本研究旨在探讨SST是否通过巨噬细胞调节非小细胞肺癌的免疫,并阐明其潜在机制。方法:采用随机行走与重启(RWR)算法初步预测免疫调节机制,随后采用Lewis肺癌模型和巨噬细胞消耗实验进行验证。通过流式细胞术、Western blot、qRT-PCR、ELISA、伤口愈合、迁移和成管实验证实SST对巨噬细胞表型和功能的调节作用。此外,采用非靶向和靶向代谢组学,结合分子研究,探讨巨噬细胞的免疫代谢机制。结果:SST治疗明显阻碍肿瘤进展,并确定巨噬细胞为增强CD8+ T细胞对肿瘤免疫的靶细胞。具体来说,SST通过向m1样表型极化,同时抑制m2样表型,减少m2驱动的血管生成和转移,对巨噬细胞进行重编程。从机制上说,SST抑制谷氨酰胺(Gln)的代谢,其中n -乙酰天冬氨酸(NAA), Gln的下游代谢物,被认为是巨噬细胞表型的关键调节因子。SST通过下调NAT8L和上调ASPA抑制NAA,从而缓解NAA介导的NF-κB活化抑制。结论:SST通过促进M1巨噬细胞和抑制M2巨噬细胞增强NSCLC抗肿瘤免疫。NAA是一种巨噬细胞来源的生物标志物,强调了SST在调节M1/M2平衡中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Phytomedicine
Phytomedicine 医学-药学
CiteScore
10.30
自引率
5.10%
发文量
670
审稿时长
91 days
期刊介绍: Phytomedicine is a therapy-oriented journal that publishes innovative studies on the efficacy, safety, quality, and mechanisms of action of specified plant extracts, phytopharmaceuticals, and their isolated constituents. This includes clinical, pharmacological, pharmacokinetic, and toxicological studies of herbal medicinal products, preparations, and purified compounds with defined and consistent quality, ensuring reproducible pharmacological activity. Founded in 1994, Phytomedicine aims to focus and stimulate research in this field and establish internationally accepted scientific standards for pharmacological studies, proof of clinical efficacy, and safety of phytomedicines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信